The Naturetic Effects of Long-Term Use of Midodrine on Patients with Liver Cirrhosis and Refractory Ascites
International Research Journal of Gastroenterology and Hepatology, Volume 6, Issue 1,
Page 93-107
Abstract
Background: splanchnic vasodilatation is a major contributor to development of ascites n cirrhotic patients and associated with poor sodium excretion. So Midodrine which is, alpha 1 agonist, may improve circulatory abnormality in cirrhotic patients via its vaso-constrictive action thus leading to better natriuresis.
Aim: to assess the efficacy and the safety of midodrine (alpha adrenergic agonist) on patients with liver cirrhosis as regard sodium excretion.
Patients and Methods: A total of 80 cirrhotic patients with refractory ascites were enrolled in this prospective study. Patients consisted of 40 patients receiving standard medical therapy (dietary salt restriction and diuretics) and 40 patients receiving standard medical therapy +Midodrine in a dose of (7.5 mg /8hours) for one month. Body weight, abdominal girth, complete blood count, liver and renal function tests, serum electrolytes and 24-h urine volume and Na level were obtained at the start and the end of the study
Results: Body weight and abdominal girth significantly decreased in midodrine group patients compared to control group (p <0.001). Also, 24-h urinary volume and Na excretion were significantly higher in midodrine group patients at the end of the study compared to SMT patients (p <0.001).
Conclusions: Midodrine could be used safely as an adjuvant to SMT (salt restriction and diuretics) in cirrhotic patients with refractory ascites in a dose of 7.5 mg TDS with better outcomes evidenced by reduced body weight and increase Na excretion in urine
- Cirrhosis
- ascites
- midodrine
- natriuresis
How to Cite
References
Sussman AN, Boyer TD. Management of refractory ascites and hepatorenal syndrome. Current gastroenterology reports. 2011;13:17-25.
Kashani A, Landaverde C, Medici V, Rossaro L. Fluid retention in cirrhosis: pathophysiology and management. QJM: An International Journal of Medicine. 2008;101(2):71-85..
Brunelli SM, Cohen DE, Marlowe G, Van Wyck D. The impact of midodrine on outcomes in patients with intradialytic hypotension. American journal of nephrology. 2018;48(5):381-8.
Biggins SW, Angeli P, Garcia‐Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2): 1014-48.
Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepatic Medicine: Evidence and Research. 2018:55-71.
Shrestha DB, Budhathoki P, Sedhai YR, Baniya RK, Karki P, Jha P, Mainali G, Acharya R, Sodhi A, Kadaria D. Midodrine in Liver Cirrhosis With Ascites: A Systematic Review and Meta-Analysis. Cureus. 2022 Jul 30;14(7).
Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, Krag A, Laleman W, Gines P. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology. 2018;69(2):406-60.
Obiedallah AA, Abdelmohsen E, Kelani AI, Mousa M. Effect of midodrine in patients with liver cirrhosis and refractory ascites. Am J Intern Med. 2017;5:12-7.
Gomaa A, Allam N, Elsharkway A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepatic Medicine: Evidence and Research. 2017:17-25.
Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E, Galioto A, Salinas F, D’Aquino M, Sticca A, Gatta A. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: Results of an open randomised clinical trial. Gut. 2010;59(01) :98-104.
Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. Journal of Hepatology. 2012;56(2):348-54.
Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. Journal of Hepatology. 2007; 46(2):213-21.
Ali A, Farid S, Amin M, Kassem M, Al-Garem N. Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: A double-blind, placebo-controlled, randomized trial. Hepatogastroenterology. 2014;61(135): 1915-24.
Rai N, Singh B, Singh A, Vijayvergiya R, Sharma N, Bhalla A, Singh V. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: A randomised pilot study. Liver International. 2017;37(3):406-14.
Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, Finucci GF, Casiglia E, Sticca A, De Toni R, Pavan L. Acute effects of the oral administration of midodrine, an α‐adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998;28(4):937-43.
Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K, Bain VG. The effect of 1 month of therapy with midodrine, octreotide‐LAR and albumin in refractory ascites: a pilot study. Liver International. 2009;29(2):169-74..
Ali A, Farid S, Amin M, Kassem M, Al-Garem N, Al-Ghobashy M. Comparative clinical pharmacokinetics of midodrine and its active metabolite desglymidodrine in cirrhotic patients with tense ascites versus healthy volunteers. Clinical Drug Investigation. 2016;36:147-55.
Patel S, Nguyen DS, Rastogi A, Nguyen MK, Nguyen MK. Treatment of cirrhosis-associated hyponatremia with midodrine and octreotide. Frontiers in Medicine. 2017;4:17.
Misra VL, Vuppalanchi R, Jones D, Hamman M, Kwo PY, Kahi C, Chalasani N. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. Alimentary Pharmacology & Therapeutics. 2010;32(8):1044-50.
Singh V, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, Bhalla A. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. Official Journal of the American College of Gastroenterology| ACG. 2013;108(4):560-7.
Kalil J, Klein J, Schadde E, Hertl M, Poirier J, Chan E. Midodrine conveys increased risk for waitlist mortality in liver transplant patients. HPB. 2018;20:S791.
Oda AM, Basuni AA, Badran HM, Aziz WF, Rewisha EA, Waked IA. Hemodynamic effects of 3 months of therapy with midodrine in cirrhotic patients with and without ascites. Egyptian Liver Journal. 2011;1(2):61-8.
Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Official Journal of the American College of Gastroenterology| ACG. 2005;100(4):879-85.
Krag A, Møller S, Henriksen JH, Holstein‐Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 2007; 46(6):1863-71.’
-
Abstract View: 0 times
PDF Download: 0 times
